The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
I'm an advisory council for Sanofi and I'm I've been an advisor about this drug so to go thousand which is part of a new class of drugs that will hopefully benefit people with type one diabetes these adjuvant therapies molecules that you take in addition to insulin I've been involved in this program now for close to seven years
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.